HIV-1-infection Completed Phase 3 Trials for Dolutegravir (DB08930)

Also known as: HIV -1 Infection / HIV1 Infection / HIV-I Infection / HIV 1 Infection / Human Immunodeficiency Virus Type 1 (HIV-1) Infection / Human Immunodeficiency Virus I Infection / Infection, Human Immunodeficiency Virus I / HIV-1 Infections / HIV-1 Infection / [X]Human immunodeficiency virus disease (disorder) / Human immunodeficiency virus [HIV] disease / [X]Unspecified human immunodeficiency virus [HIV] disease (disorder) / HIV disease / (AIDS) or (HIV infection) / HTLV-III/LAV infection -RETIRED- / HIV infection NOS / Human immunodeficiency virus syndrome / Human immunodeficiency virus infection, unspecified / HIV Infections / HIV infection / Human immunodeficiency virus infection (disorder)

IndicationStatusPhase
DBCOND0054009 (HIV-1-infection)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02777229Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited SettingsTreatment
NCT02603120Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedTreatment
NCT01966822Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral DensityTreatment
NCT01227824A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice DailyTreatment
NCT01263015A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)Treatment